论著

肺炎支原体肺炎继发儿童感染性心内膜炎临床特征与诊治分析

  • 刘敏 ,
  • 王琪 ,
  • 苏军 ,
  • 崔利丹 ,
  • 孙绘霞 ,
  • 宁文慧
展开
  • 河南省儿童医院 郑州儿童医院(郑州大学附属儿童医院)(河南郑州 450000)
苏军 电子信箱:sujun618794@126.com

收稿日期: 2025-02-10

  录用日期: 2025-08-04

  网络出版日期: 2026-01-05

Clinical features, diagnosis, and treatment of Mycoplasma pneumoniae pneumonia secondary to infective endocarditis in children

  • LIU Min ,
  • WANG Qi ,
  • SU Jun ,
  • CUI Lidan ,
  • SUN Huixia ,
  • NING Wenhui
Expand
  • Henan Children's Hospital; Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, Henan, China

Received date: 2025-02-10

  Accepted date: 2025-08-04

  Online published: 2026-01-05

摘要

目的 探讨儿童肺炎支原体肺炎(MPP)合并感染性心内膜炎(IE)这一罕见并发症的临床特点、诊断、治疗及预后,以提高临床医生对该疾病的认识和早期诊断。方法 回顾性分析2023年1月至2024年11月本院收治的5例MPP合并IE患儿的临床资料,包括临床表现、实验室检查、影像学结果、病原学检测、治疗及随访情况。结果 5例患儿发病年龄9(5~9.5)岁,男女比例3∶2,所有患儿均有发热、咳嗽表现,仅1例合并剑突下疼痛;发热持续时间12(9.5~15)天,发现赘生物时间为病程第10(8~12)天;所有患儿均经超声心动图诊断,D二聚体5.09(4.35~7.90)μg/mL 及FDP 10.56(7.20~24.71) mg/L明显增高,IL-6 55.45(33.02~95.56 ) pg/mL及乳酸脱氢酶746(568.45~838.9) U/L水平亦有增高。所有患儿呼吸道标本MP核酸检测阳性,但仅1例血流宏基因检测检出MP。所有患儿均接受手术切除赘生物,术后病理均证实为IE。经手术治疗后所有患者均给予抗感染及抗凝治疗,3例合并肺栓塞患者出院后继续给予抗凝治疗1~6个月。出院后复查彩色多普勒超声心动图均未见赘生物复发,无气促、胸痛、喘息等症状。结论 MPP所致感染性心内膜炎早期症状隐匿,缺乏特异性临床表现。MPP患儿若伴高凝状态,建议行彩色多普勒超声心动图筛查以便早期发现IE赘生物,避免漏诊,及时治疗预后良好。

本文引用格式

刘敏 , 王琪 , 苏军 , 崔利丹 , 孙绘霞 , 宁文慧 . 肺炎支原体肺炎继发儿童感染性心内膜炎临床特征与诊治分析[J]. 临床儿科杂志, 2026 , 44(1) : 25 -30 . DOI: 10.12372/jcp.2026.25e0096

Abstract

Objective To investigate the clinical features, diagnosis, treatment, and prognosis of the rare complication of infectious endocarditis (IE) in children with Mycoplasma pneumoniae pneumonia (MPP), aiming to enhance clinicians' understanding and facilitate early diagnosis of this condition. Methods A retrospective analysis was conducted on the clinical data of 5 children with MPP complicated by IE admitted to our hospital from January 2023 to November 2024. The analysis included clinical manifestations, laboratory tests, imaging findings, etiological test results, treatment, and follow-up information. Results The median age of onset was 9 years (5-9.5) years, with a male-to-female ratio of 3:2. All patients presented with fever and cough; only one exhibited concomitant subxiphoid pain. Median duration of fever was 12 (9.5-15) days, and vegetations were detected on echocardiography at a median of 10 (8-12) days after disease onset. Elevated D-dimer levels 5.09 (4.35-7.9) μg/mL and fibrin degradation products 10.56 (7.2-24.71) mg/L indicated marked hypercoagulability, while increased IL-6 55.45 (33.02-95.56) pg/mL and lactate dehydrogenase 746 (568.45-838.9) U/L suggested significant systemic inflammation and tissue injury. All children tested positive for MP nucleic acid in respiratory specimens; however, only one had MP DNA detected in blood via metagenomic next-generation sequencing (mNGS). All underwent surgical excision of vegetations, with histopathological examination confirming the diagnosis of IE. Postoperatively, all received antimicrobial therapy and anticoagulation. Among them, three patients with confirmed pulmonary embolism continued long-term anticoagulation for 1-6 months post-discharge. Follow-up echocardiography revealed no vegetation recurrence, and no patient reported symptoms such as dyspnea, chest pain, or wheezing during the monitoring period. Conclusion MPP-related IE presents with nonspecific and often insidious early manifestations, posing challenges for timely diagnosis. In pediatric patients with MPP and evidence of hypercoagulability, routine echocardiographic screening is strongly recommended to enable early detection of IE and prevent diagnostic delays. With prompt diagnosis and comprehensive management, the prognosis is favorable.

参考文献

[1] Narita M. Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis[J]. Front Microbiol, 2016, 7: 23.
[2] Subspecialty Group of Respiratory, the Society of Pediatrics, Chinese Medical Association, et al. Evidence-based guideline for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023)[J]. Zhonghua Erke Zazhi, 2024, 62(12): 1137-1144.
[3] Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-international society for cardiovascular infectious diseases criteria for infective endocarditis: updating the modified Duke criteria[J]. Clin Infect Dis, 2023, 77(4): 518-526.
[4] Popat K, Barnardo D, Webb-Peploe M. Mycoplasma pneumoniae endocarditis[J]. Br Heart J, 1980, 44(1):111-112.
[5] 张旭. 一例感染性心内膜炎合并肺炎支原体感染患者抗感染药物应用的病例分析[J]. 临床检验杂志(电子版), 2020, 9(3): 530-531.
  Zhang X. A case analysis of anti-infective drug therapy in a patient with infective endocarditis complicated by Mycoplasma pneumoniae infection[J]. Linchuang Jianyan Zazhi(Electronic Edition), 2020, 9(3): 530-531.
[6] Dawood H, Nasir S, Khair RM, et al. Infective endocarditis secondary to Mycoplasma pneumoniae[J]. Cureus, 2021, 13(8): e17461.
[7] Scapini JP, Flynn LP, Sciacaluga S, et al. Confirmed Mycoplasma pneumoniae endocarditis[J]. Emerg Infect Dis, 2008, 14(10):1664-1665.
[8] Holland TL, Baddour LM, Bayer AS, et al. Infective endocarditis[J]. Nat Rev Dis Primers, 2016, 2: 16059.
[9] Hu J, Ye Y, Chen X, et al. Insight into the pathogenic mechanism of myco- plasma pneumoniae[J]. Curr Microbiol, 2022, 80(1): 14.
[10] Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumoniaJournal of infection and chemotherapy[J]. J Infect Chemother, 2010, 16(3): 162-169.
[11] Fan Q, Meng J, Li P, et al. Pathogenesis and association of Mycoplasma pneumoniae infection with cardiac and hepatic damage[J]. Microbiol Immunol, 2015, 59(7): 375-380.
[12] Yakut K, Ecevit Z, Tokel NK, et al. Infective endocarditis in childhood: a single-center experience of 18 years[J]. Braz J Cardiovasc Surg, 2021, 36(2): 172-182.
[13] Ajmi H, Herch R, ElGhali H, et al. Epidemiological, bacteriological, and evolutive features of children hospitalized for infective endocarditis in a tertiary Tunisian pediatric department[J]. J Saudi Heart Assoc, 2023, 35(4): 339-345.
[14] 徐克, 王山山, 杨慧, 等. 感染性心内膜炎患者病原菌特征、心肌酶谱水平及疾病转归因素分析[J]. 分子诊断与治疗杂志, 2024, 16(6): 1091-1094.
  Xu K, Wang SS, Yang H, et al. Analysis of pathogen characteristics, myocardial enzyme levels and factors affecting disease outcome in patients with infective endocarditis[J]. Fenzi Zhenduan Yu Zhiliao Zazhi, 2024, 16(6):1091-1094.
[15] Bustos-Merlo A, Rosales-Castillo A, Cobo F, et al. Blood culture-negative infective endocarditis by mycoplasma hominis: case report and literature review[J]. J Clin Med, 2022, 11(13): 3841.
[16] 中华医学会胸心血管外科分会瓣膜病外科学组. 感染性心内膜炎外科治疗中国专家共识[J]. 中华胸心血管外科志, 2022, 38(3): 146-155.
  Valvular Surgery Group, Chinese Society for Thoracic and Cardiovascular Surgery, Chinese Medical Association. Chinese expert consensus on surgical treatment of infective endocarditis[J]. Zhonghua Xiongxinxueguan Waike Zazhi, 2022, 38(3): 146-155.
[17] 程真莉, 张祯祯. 重视儿童感染性心内膜炎的诊治[J]. 临床儿科杂志, 2024, 42(10): 902-906.
  Cheng ZL, Zhang ZZ. Emphasis on the diagnosis and treatment of infective endocarditis in children[J]. Linchuang Erke Zazhi, 2024, 42(10): 902-906.
[18] 李雪雪. 儿童肺炎支原体肺炎合并血液高凝状态的研究进展[J]. 国际儿科学杂志, 2019, 46(2): 105-108.
  Li XX. Research progress on Mycoplasma pneumoniae pneumonia complicated with hypercoagulable state in children[J]. Guoji Erkexue Zazhi, 2019, 46(2): 105-108.
文章导航

/